Oruka Therapeutics, Inc.
🇺🇸United States
ORIC Pharmaceuticals Announces Promising Early Data for ORIC-944 and Collaboration for ORIC-114
• ORIC Pharmaceuticals reported encouraging early data from a Phase 1b trial of ORIC-944 combined with apalutamide in metastatic castration-resistant prostate cancer (mCRPC).
• The company entered a clinical trial collaboration with Johnson & Johnson to evaluate ORIC-114 with amivantamab for first-line treatment of NSCLC with EGFR exon 20 insertion mutations.
• ORIC anticipates seven data readouts across ORIC-114 and ORIC-944 programs in the next 18 months, potentially leading to registrational trials in 2025 and 2026.
Oruka Therapeutics Initiates Phase 1 Trial of ORKA-001, a Novel IL-23p19 Antibody
• Oruka Therapeutics has commenced a Phase 1 clinical trial of ORKA-001, a novel monoclonal antibody targeting IL-23p19, administered subcutaneously.
• The trial aims to evaluate the pharmacokinetic profile and safety of ORKA-001 in healthy volunteers, with data expected in the second half of 2025.
• A proof-of-concept study in psoriasis is planned for the second half of 2025, with initial efficacy data anticipated in the second half of 2026.
• Preclinical data suggest ORKA-001 could allow for less frequent dosing compared to current treatments, potentially once or twice yearly.
© Copyright 2025. All Rights Reserved by MedPath